Survivin was initially identified as a member of the inhibitor apoptosis (IAP) protein family and has been shown to play a critical role in the regulation of apoptosis. More recent studies showed that survivin is a component of the chromosome passenger complex and acts as an essential mediator of mitotic progression. Other potential functions of survivin, such as mitochondrial function and autophagy, have also been proposed. Survivin has emerged as an attractive target for cancer therapy because its overexpression has been found in most human cancers and is frequently associated with chemotherapy resistance, recurrence, and poor survival rates in cancer patients. In this review, we discuss our current understanding of how survivin mediates various aspects of malignant transformation and drug resistance, as well as the efforts that have been made to develop therapeutics targeting survivin for the treatment of cancer.
存活蛋白最初被鉴定为凋亡抑制蛋白家族成员，在细胞凋亡调控中发挥关键作用。近年研究表明，存活蛋白作为染色体乘客复合体的重要组分，在细胞有丝分裂进程中发挥核心调控功能。该蛋白在线粒体功能与自噬等细胞过程中的潜在作用也逐步被揭示。由于在绝大多数人类肿瘤中均检测到存活蛋白的异常高表达，且其表达水平常与化疗耐药、肿瘤复发及患者不良预后密切相关，该蛋白已成为极具潜力的肿瘤治疗靶点。本文系统综述了存活蛋白在恶性肿瘤转化及耐药机制中的多重生物学功能，并总结了目前针对该靶点的抗肿瘤药物研发进展。
Survivin as a Therapeutic Target for the Treatment of Human Cancer
肿瘤(癌症)患者之家